Johannes Laimer

Publication Activity (10 Years)

Years Active: 2021-2021
Publications (10 Years): 6

Top Topics

Peritoneal Dialysis

Ejection Fraction

Coronavirus Disease

Top Venues

Healthcare (Basel, Switzerland)

Future oncology (London, England)

International journal of environmental research and public health

This page only lists publications with an associated author ORCID identifier.

Publications

Vera Wiesmüller, Emanuel Bruckmoser, Ines Kapferer-Seebacher, Katharina Fink, Sabrina Neururer, Dagmar Schnabl, Johannes Laimer
Dentists' Working Conditions during the First COVID-19 Pandemic Lockdown: An Online Survey. Healthcare (Basel, Switzerland) 9 (3) (2021)
Emanuel Bruckmoser, Miriam Palaoro, Lukas Latzko, Dagmar Schnabl, Sabrina B Neururer, Johannes Laimer
Choosing the Right Partner for Medication Related Osteonecrosis of the Jaw: What Central European Dentists Know. International journal of environmental research and public health 18 (9) (2021)
Lukas Latzko, Bernd Schöpf, Hansi Weissensteiner, Federica Fazzini, Liane Fendt, Eberhard Steiner, Emanuel Bruckmoser, Georg Schäfer, Roy-Cesar Moncayo, Helmut Klocker, Johannes Laimer
Implications of Standardized Uptake Values of Oral Squamous Cell Carcinoma in PET-CT on Prognosis, Tumor Characteristics and Mitochondrial DNA Heteroplasmy. Cancers 13 (9) (2021)
Johannes Laimer, Martin Hechenberger, Johanna Maria Lercher, Eva Born, Michael Schomaker, Sibylle Puntscher, Uwe Siebert, Emanuel Bruckmoser
New Perspective for Soft Tissue Closure in Medication-Related Osteonecrosis of the Jaw (MRONJ) Using Barbed Sutures. Journal of clinical medicine 10 (8) (2021)
Johannes Laimer, Alexander Höller, Ute Pichler, Raphael Engel, Sabrina B Neururer, Alexander Egger, Andrea Griesmacher, Emanuel Bruckmoser
Nutritional Status in Patients with Medication-Related Osteonecrosis of the Jaw (MRONJ). Nutrients 13 (5) (2021)
Johannes Laimer, Martin Hechenberger, Daniela Müller, Benjamin Walch, Andreas Kolk, Dagmar Schnabl, Michael Schomaker, Emanuel Bruckmoser
Dental pathologies in tumor patients with bone metastases or multiple myeloma scheduled for antiresorptive therapy. Future oncology (London, England) 17 (21) (2021)